Cumberland Pharmaceuticals Inc
CPIX
View Detailed Chart
4.650USD
-0.110-2.31%
Close 01/16, 16:00（ET）Quotes delayed by 15 min
69.55MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.31%
5 Days
-6.06%
1 Month
+19.54%
6 Months
+25.34%
Year to Date
+16.83%
1 Year
+83.79%
View Detailed Chart
TradingKey Stock Score of Cumberland Pharmaceuticals Inc
Currency: USD Updated: 2026-01-16Key Insights
Cumberland Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 77 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 0.00.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cumberland Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Cumberland Pharmaceuticals Inc Highlights
StrengthsRisks
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Growing
The company is in a growing phase, with the latest annual income totaling USD 37.87M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 37.87M.
Undervalued
The company’s latest PE is -20.10, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 3.43M shares, decreasing 18.42% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 515.47K shares of this stock.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Cumberland Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Cumberland Pharmaceuticals Inc Info
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
Ticker SymbolCPIX
CompanyCumberland Pharmaceuticals Inc
CEOKazimi (A. J)
Websitehttps://www.cumberlandpharma.com/
FAQs
What is the current price of Cumberland Pharmaceuticals Inc (CPIX)?
The current price of Cumberland Pharmaceuticals Inc (CPIX) is 4.650.
What is the symbol of Cumberland Pharmaceuticals Inc?
The ticker symbol of Cumberland Pharmaceuticals Inc is CPIX.
What is the 52-week high of Cumberland Pharmaceuticals Inc?
The 52-week high of Cumberland Pharmaceuticals Inc is 7.250.
What is the 52-week low of Cumberland Pharmaceuticals Inc?
The 52-week low of Cumberland Pharmaceuticals Inc is 1.850.
What is the market capitalization of Cumberland Pharmaceuticals Inc?
The market capitalization of Cumberland Pharmaceuticals Inc is 69.55M.
What is the net income of Cumberland Pharmaceuticals Inc?
The net income of Cumberland Pharmaceuticals Inc is -6.48M.
Is Cumberland Pharmaceuticals Inc (CPIX) currently rated as Buy, Hold, or Sell?
According to analysts, Cumberland Pharmaceuticals Inc (CPIX) has an overall rating of Hold, with a price target of --.
What is the Earnings Per Share (EPS TTM) of Cumberland Pharmaceuticals Inc (CPIX)?
The Earnings Per Share (EPS TTM) of Cumberland Pharmaceuticals Inc (CPIX) is -0.231.
Related Instruments
+0.53%
-0.41%
-1.11%
+0.43%
+0.83%
-1.93%
+9.12%
+0.12%
+3.01%
-0.93%
-1.85%
-2.40%
+0.56%
-0.43%
-1.83%
+0.61%
-1.20%
0.00%
-0.50%
-1.04%Popular Symbols
255.530
-2.680 (-1.04%)
186.230
-0.820 (-0.44%)
94944.790
-403.390 (-0.42%)
221.510
-0.590 (-0.27%)
3316.330
+1.490 (+0.04%)
437.500
-1.070 (-0.24%)
4582.090
-23.500 (-0.51%)
59.265
+0.426 (+0.72%)
1.160
-0.000 (-0.04%)
158.074
-0.566 (-0.36%)
